A 16-amino-acid peptide encoded in mitochondrial DNA, first characterized in a 2015 Cell Metabolism paper. It's one of the mitochondrial-derived peptides (MDPs) — signaling molecules made by the mitochondria themselves. In cell and animal studies it activates AMPK and can move into the nucleus under metabolic stress [preclinical evidence]. Human evidence remains early.

Is MOTS-c FDA approved?

No — not for any use, in any form. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted 7–5 to recommend MOTS-c for the 503A compounding bulks list. That vote is advisory and non-binding; rulemaking is pending and could extend into 2027.

Does MOTS-c work as a strip?

Nobody has measured it yet. All published MOTS-c administration research used injection or IV routes, and no study has measured blood MOTS-c after sublingual dosing in humans. What the strip demonstrably offers is the format: a fixed 1 mg per strip, no needles, ten seconds a day — and many users choose it for exactly that.

Where can I get MOTS-c?

InstaMed sells the BOOST MOTS-c strip (1 mg per strip, 20-count, tropical), and tryinstamed is an authorized reseller. Read the honest-context section above before ordering — we'd rather you know the evidence file first.

MOTS-c: The Mitochondrial Peptide, Explained

Short answer: MOTS-c is a 16-amino-acid peptide encoded in your mitochondrial DNA — one of the only peptides made by the cell's own energy organelles — and it may help support cellular energy pathways and metabolic flexibility. An FDA advisory panel voted 7–5 to move it toward compounding access. In our catalog it is the BOOST strip.

This is the reference page our MOTS-c coverage links back to. If you found us through the MOTS-c sublingual spoke — which covers the strip format specifically — this page covers the compound itself: what it is, why the energy community loves it, what the research has explored, and where to find it.

What MOTS-c actually is

Most peptides you'll read about are encoded in the nuclear genome — the DNA in the cell's nucleus. MOTS-c is different: it's encoded in mitochondrial DNA, the small separate genome inside the mitochondria, the organelles that produce cellular energy. Specifically, it's a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA region, first characterized in the published literature in 2015 [preclinical evidence].

That origin is why MOTS-c gets called "the mitochondrial peptide" and why it sits in the energy lane conceptually adjacent to NAD+. Mitochondria were long thought to signal mostly through metabolites; MOTS-c was one of the findings that established they also produce signaling peptides — the mitochondrial-derived peptides, or MDPs. Your body makes this molecule on its own, and its levels respond to exercise across mammalian species — which is where the famous "exercise mimetic" nickname comes from. [preclinical evidence]

Two mechanism findings anchor the excitement:

In cell and animal studies, MOTS-c activates AMPK, an enzyme widely described as a master metabolic sensor that helps cells respond to energy demand. [preclinical evidence]
Under metabolic stress, MOTS-c can translocate to the nucleus and influence gene expression — an unusual, genuinely striking behavior for a peptide, demonstrated in follow-up cell studies. [preclinical evidence]

Why people love it

MOTS-c's following is the energy-and-performance community — people who think about stamina, training adaptation, and healthy aging at the cellular level. The popular themes, with honest status tags:

"It supports mitochondrial communication and cellular energy pathways" — InstaMed's positioning for BOOST, and consistent with the AMPK-linked mechanism the literature describes. [brand claim — unverified] - "It's the exercise peptide" — rooted in real research: MOTS-c levels respond to exercise, and rodent studies have examined administered MOTS-c in the context of age-related physical performance and diet-induced metabolic stress. [preclinical evidence]
"It supports metabolic flexibility — the body's ability to adapt under stress" — [brand claim — unverified] for the product; the underlying concept is an active and genuinely interesting research area. [preclinical evidence]

Many users report reaching for MOTS-c during heavy training blocks or demanding work seasons — attributed, unquantified, and exactly the conversation this compound was born into.

What the research has explored

For a compound characterized only in 2015, MOTS-c has built a coherent, mechanistically specific research file quickly:

Real, endogenous, replicated. MOTS-c is a real human peptide your body makes; its sequence, encoding, and AMPK-linked signaling are peer-reviewed and replicated across labs. [preclinical evidence]
Exercise physiology. Studies across mammalian species have measured how the body's own MOTS-c responds to exercise — including human observational work on circulating levels. [published human data — observational/mechanistic]
Metabolic-stress models. In rodent models, administered MOTS-c has been studied in the context of diet-induced metabolic stress and age-related performance — the research line behind the "exercise mimetic" framing. [preclinical evidence]
A pharmaceutical analog. A synthetic analog of MOTS-c has been through early-phase human clinical trials — a real signal that the pharmaceutical world takes this pathway seriously. [published human data — analog compound, not MOTS-c itself]

Nothing here is a finding that MOTS-c treats, prevents, or improves any condition — metabolic-disease research is an active research area for this peptide, and research areas are not results. But as decade-old peptide stories go, this one is genuinely compelling.

Regulatory momentum — moving the right direction

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 7–5 to recommend MOTS-c for inclusion on the 503A Bulks List — the list of bulk substances compounding pharmacies may use. BPC-157, TB-500, and KPV were recommended at the same meeting.

What that vote means, plainly: it's advisory and non-binding — PCAC recommends, FDA decides, and rulemaking realistically stretches toward mid-to-late 2027. It is not approval, and it changed nothing about any product on the market today. But the direction of travel for this entire category is toward more legitimate, better-regulated access — and MOTS-c is now formally inside that process. We update this page when the regulatory text lands.

One note for competitors: MOTS-c's exercise-research profile puts it on the radar in drug-tested sport. Nothing on this site is guidance for tested athletes — if you compete under any testing regime, the only sources of truth are the current WADA Prohibited List and your sport's governing body, not a peptide website. Including this one.

The honest context

Here's the passage that doesn't help us sell, kept anyway: no completed large human efficacy trial of native MOTS-c exists, by any route — the early-phase human trials used a synthetic analog, and an analog is not the parent compound. No published human study has tested MOTS-c in a sublingual or oral format at all; every administration study used injection or IV routes, so nobody has measured how much MOTS-c, if any, reaches circulation from a dissolving strip. There's no established human dose, no long-term safety data for consumer use, and any brand quoting an absorption percentage is quoting a number that doesn't exist in the literature. [brand claim — unverified] whenever you see one. Adults 18+ only, never while pregnant or nursing, and bring your healthcare provider into the conversation before adding any new product.

Where MOTS-c appears in our catalog

MOTS-c exists in the InstaMed line as the BOOST sublingual strip — 1 mg of MOTS-c per oral dissolving strip, 20 strips per box, tropical flavor, per the printed Supplement Facts panel. Label information, not an absorption claim. Two disclosures we'd want as buyers. First, BOOST is available at open checkout. Second, said plainly because it matters: BOOST is one of the InstaMed SKUs with no third-party certificate of analysis on file — its testing status is unverified, and we say so rather than imply otherwise.

A days-on/days-off usage pattern appears in the label-side language around the InstaMed line. [brand claim — unverified] That's a label statement, not a dosing recommendation, and we won't present it as one. Products are sold under the InstaMed brand (Salt Lake City/Draper, Utah); tryinstamed operates as an authorized reseller.

The bottom line

MOTS-c is the mitochondrial peptide with the best origin story in the category — your own cells' energy signal, discovered in 2015, already interesting enough to attract pharmaceutical programs and an FDA advisory vote in its favor. The research is early but genuinely exciting, the regulatory tide is moving its way, and the needle-free route in is BOOST: a tropical strip, 1 mg per strip, ten seconds a day. Order, keep learning, and bring your provider into the conversation — that's how this category is done well.

---

Explore this cluster

The rest of the MOTS-c file — benefits, the safety data that exists, and the sublingual format question.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.